SANGUINE CORP. (SGNC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike Ankley who wrote (3360)	7/18/1998 4:13:00 AM
From: Mike Ankley	of 5402

Green Cross assigned U.S. patent 5,214,214 Perfluoro branched alkyl ethers and emulsions patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. Abstract ------------------------------------------------------------------------ There is provided a novel perfluorochemical represented by the formula, ##STR1## wherein R(F) is a perfluoroalkyl group, a perfluoro alkoxyalkyl group or a perfluoroalkyloxy group, X and X' are same as or different from each other and are a fluorine atom or a perfluoroalkyl group, and Y is a perfluoroalkyloxy group or a perfluoro dialkylamino group, the total number of the carbon atoms contained being an integer of 8 to 11 inclusive. The perfluorochemical is prepared by perfluorinating the corresponding partially fluorinated compound which may have unsaturated hydrocarbon moiety, only with molecular fluorine in a stoichiometric excess amount in an inert solvent. The perfluorochemical is used for preparing a stable emulsion as blood substitutes or perfusion media. Cheers Mike

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next